Biotech Equities Technical Momentum -- Research on Organovo, Prana Biotechnology, Isis Pharma, and Pharmacyclics

LONDON, July 14, 2014 /PRNewswire/ --

On Friday, July 11, 2014, the NASDAQ Composite ended at 4,415.49, up 0.44%, the Dow Jones Industrial Average advanced 0.17%, to finish the day at 16,943.81, and the S&P 500 closed at 1,967.57, up 0.15%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 712.90, up 0.14%, with the index also advancing 10.01% in the previous three months. Investor-Edge has initiated coverage on the following equities: Organovo Holdings Inc. (NYSE MKT: ONVO), Prana Biotechnology Ltd (NASDAQ: PRAN), Isis Pharmaceuticals Inc. (NASDAQ: ISIS) and Pharmacyclics Inc. (NASDAQ: PCYC). Free technical research on ONVO, PRAN, ISIS and PCYC can be downloaded upon signing up at:

http://www.investor-edge.com/4817-register

Organovo Holdings Inc.'s stock advanced 3.12%, to close the day at $7.93. The stock recorded a trading volume of 0.65 million shares, much below its three months average volume of 1.60 million shares. The stock oscillated between $7.71 and $8.06 during the session. Over the last one month and over the past three months, Organovo Holdings Inc.'s shares have gained 15.43% and 9.23%, respectively. However, the stock has lost 28.36% since the start of this year. The stock is trading above its 50-day moving average of $7.22, while the 50-day moving average is below Organovo Holdings Inc.'s 200-day moving average of $8.23. Additionally, the stock has a Relative Strength Index (RSI) of 51.40. Sign up today to read free research on ONVO at:

http://www.investor-edge.com/4817-ONVO-14Jul2014.pdf

On Friday, shares in Prana Biotechnology Ltd recorded a trading volume of 1.37 million shares, close to its three months average volume of 1.31 million shares. The stock ended the day at $2.61, which was 1.95% above its previous day's closing of $2.56, and registered an intraday range of $2.45 and $2.68. Prana Biotechnology Ltd's shares have surged 9.21% in the previous three trading sessions and 30.50% in the last one month. However, the stock has lost 62.77% since the start of this year. The company's stock is trading above its 50-day moving average of $1.93. Furthermore, shares of the company have an RSI of 70.44. Sign up today to read free research on PRAN at:

http://www.investor-edge.com/4817-PRAN-14Jul2014.pdf

Isis Pharmaceuticals Inc.'s stock finished the Friday's session 1.72% higher at $30.83. A total of 1.21 million shares were traded, which was below its three months average volume of 2.89 million shares. The stock moved between $30.12 and $31.17 during the session. Over the last three trading sessions and the previous one month, Isis Pharmaceuticals Inc.'s shares have declined 1.50% and 8.33%, respectively. Additionally, the company's stock has lost 22.62% since the beginning of this year. The stock is trading above its 50-day moving average of $30.05, while the 50-day moving average is below Isis Pharmaceuticals Inc.'s 50-day moving average of $38.18. Isis Pharmaceuticals Inc.'s stock has an RSI of 41.44. Sign up today to read free research on ISIS at:

http://www.investor-edge.com/4817-ISIS-14Jul2014.pdf

On Friday, shares in Pharmacyclics Inc. traded between $95.53 and $98.21 before ending the session 1.51% lower at $95.69. Pharmacyclics Inc.'s stock reported a trading volume of 0.68 million shares, below its three months average volume of 1.40 million shares. Shares of the company traded at a PE ratio of 54.37. Pharmacyclics Inc.'s shares have advanced 0.63% in the last one month and 11.13% in the previous three months. However, the stock has lost 9.54% since the start of this year. The stock is trading above its 50-day moving average of $93.46. Moreover, shares of the company have an RSI of 56.34. Sign up today to read free research on PCYC at:

http://www.investor-edge.com/4817-PCYC-14Jul2014.pdf


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED